Galaxy Biotech, LLC

1230 Bordeaux Dr

Sunnyvale, CA 94089



Product Candidates currently available for licensing

HuL2G7 humanized monoclonal antibody (mAb) to Hepatocyte Growth Factor (HGF).   In 2006, Galaxy licensed worldwide development and marketing rights for this product candidate to Takeda Pharmaceutical Company, one of the 20 largest global pharma companies.  Takeda paid Galaxy a licensing fee and provided research funding and milestone payments. Takeda performed all preclinical and manufacturing activities needed to file an IND for HuL2G7 and conducted a Phase I clinical trial in advanced non-hematologic malignancies in 2009-2010, in which the mAb displayed an excellent preliminary safety profile and indication of activity. However, due to its strategic prioritization, Takeda returned all rights to HuL2G7 to Galaxy in July, 2012. Galaxy is therefore currently seeking a new, committed corporate partner/licensee for development of HuL2G7, worldwide or in specific geographic areas.

Licensing terms

In return for exclusive development and marketing rights, Galaxy expects a licensing fee, milestone payments, and royalties on product sales.  Co‑promotion rights and/or an equity investment are not expected.


Companies that wish to discuss the Galaxy product candidates available for licensing, please contact:


Cary Queen, Ph.D.
Galaxy Biotech, LLC
Tel: 408-446-2691
Fax: 408-446-2694